Skip to content
HowShorted

LIGAND PHARMACEUTICALS INC short interest in 2019

In 2019, LIGAND PHARMACEUTICALS INC's disclosed short interest ran from 37.21% of shares outstanding on 15 Jan 2019 to 44.26% on 31 Dec 2019, a change of +7.05 percentage points. The year's high was 44.26% on 31 Dec 2019 and its low 32.15% on 31 Jul 2019, averaging 37.11% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 33.20 days on 31 Dec 2019. Full history: LIGAND PHARMACEUTICALS INC.

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for LIGAND PHARMACEUTICALS INC in 2019

2019 in figures

Start of year
37.21% (15 Jan 2019)
End of year
44.26% (31 Dec 2019)
Change
+7.05 pp
High
44.26% (31 Dec 2019)
Low
32.15% (31 Jul 2019)
Average
37.11%
Highest days to cover
33.20 (31 Dec 2019)
SEC filings marked
8

Every report in 2019

LIGAND PHARMACEUTICALS INC short interest in 2019
SettlementShort interestDays to coverFilings since previous
15 Jan 201937.21%14.26
31 Jan 201939.23%5.77
15 Feb 201938.88%14.87results (8-K)
28 Feb 201938.24%17.3510-K filed
15 Mar 201933.37%7.41
29 Mar 201934.46%14.71
15 Apr 201933.90%23.29
30 Apr 201933.15%20.63
15 May 201935.80%17.55results (8-K), 10-Q filed
31 May 201935.32%28.58
14 Jun 201935.96%21.63
28 Jun 201934.58%16.12
15 Jul 201932.98%20.91
31 Jul 201932.15%13.91results (8-K)
15 Aug 201935.16%14.2610-Q filed
30 Aug 201934.36%21.70
13 Sep 201933.97%11.26
30 Sep 201938.48%13.96
15 Oct 201938.84%26.46
31 Oct 201939.24%29.63
15 Nov 201943.56%17.04results (8-K), 10-Q filed
29 Nov 201943.67%24.95
13 Dec 201943.76%25.39
31 Dec 201944.26%33.20

See also: LIGAND PHARMACEUTICALS INC's full history · most shorted US stocks of 2019 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.